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SDHDGerm line heterozygous mutations in the structural subunit genes of mitochondrial complex II (succinate dehy-
drogenase; SDH) and the regulatory gene SDHAF2 predispose to paraganglioma tumorswhich show constitutive
activation of hypoxia inducible pathways. Mutations in SDHD and SDHAF2 cause highly penetrant multifocal
tumor development after a paternal transmission, whereas maternal transmission rarely, if ever, leads to
tumor development. This transmission pattern is consistent with genomic imprinting. Recent molecular evi-
dence supports a model for tissue-speciﬁc imprinted regulation of the SDHD gene by a long range epigenetic
mechanism. In addition, there is evidence of SDHB mRNA editing in peripheral blood mononuclear cells and
long-term balancing selection operating on the SDHA gene. Regulation of SDH subunit expression by diverse epi-
genetic mechanisms implicates a crucial dosage-dependent role for SDH in oxygen homeostasis. This article is
part of a Special Issue entitled: Respiratory complex II: Role in cellular physiology and disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Identiﬁcation of germ line heterozygous mutations in SDH genes in
hereditary paraganglioma and pheochromocytoma (PGL/PHEO) families
highlighted an essential role for mitochondria in tumor suppression
[1–4]. Mutations in the mitochondrial complex II structural subunit
genes SDHB, SDHC and SDHD and the regulatory subunit gene SDHAF2
were described in many PGL families. SDHB encodes the hydrophilic
catalytical iron–sulfur-containing subunit. SDHC and SDHD encode the
two hydrophobic subunits that span the inner mitochondrial membrane
and sandwich a single heme moiety [5]. SDHAF2 is a recently character-
ized regulatory subunit essential for ﬂavination of the major catalytical
subunit encoded by SDHA [4]. Mutations in SDHAwere described in sev-
eral isolated but not in familial paraganglioma cases [6,7]. PGL tumors de-
rive from paraganglia, highly specialized small neuroendocrine organs
and clusters of tissues located internally near large vessels and nerves
[8]. Carotid body, a small oxygen-sensing organ located at the bifurcation
of the common carotid artery in the neck and adrenalmedulla, located in-
side of the adrenal glands in the retroperitoneumabove the kidneys is the
most prominent paraganglionic organ. Large-scale mutation analyses of, Pheochromocytoma; SDHAF2,
CF, CCCTC-binding factor (zinc
ge intergenic non-coding RNA;
ry of SDHD locus); ROS, reactive
tory complex II: Role in cellular
rights reserved.isolated PGL and PHEO (a hormone secreting type of paraganglioma lo-
cated in adrenal medulla) cases uncovered a high incidence of occult
germ line mutations in SDH genes [9]. Clinical aspects of PGL/PHEO, in-
cluding mutation detection, imaging and treatment have been reviewed
recently [10]. Here, the focus will be on the evidence for epigenetic regu-
lation of SDH subunits.
2. Imprinted transmission of SDHD and SDHAF2 mutations
First evidence of imprinted transmission of SDHDmutations was de-
scribed in 1989 [11], even before the gene location (PGL1 locus) was
pinpointed by linkage analysis to chromosome band 11q23 in extensive
multigenerational Dutch pedigrees [12]. Genetic analyses showed that
paraganglioma tumors developed only if the mutation was transmitted
by a father. No evidence of tumor development was seen upon maternal
transmission ofmutation. The parent-of-origin effect was overwhelming-
ly conﬁrmed in other PGL1 families before discovery of the underlying
gene, SDHD [13,14]. Interestingly, a distinct paraganglioma locus named
PGL2 which was mapped to chromosome 11q13 in other Dutch families
also showed a similar pattern of parent-of-origin effect: the tumors devel-
oped only after a paternalmutation transmission [15]. The PGL2 locuswas
recently identiﬁed as the SDHAF2 gene by discovery of a single recurrent
mutation resulting in Gly-to-Arg substitution at codon 78 [4]. Recent in-
vestigation of an extended PGL2 family conﬁrms that tumor development
occurs exclusively after paternal transmission of SDHAF2mutations con-
sistent with genomic imprinting [16]. Notably, the mutations in SDHB
and SDHC, located on chromosome bands 1p51 and 1q23, respectively,
do not show evidence of imprinted transmission because eithermaternal
or paternal transmission of mutations causes tumor development.
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SDHAF2 mutations is unusual for classical tumor suppressor genes and
suggests functional differences between maternal and paternal alleles
consistentwith genomic imprinting. Genomic imprinting causes unequal
expression of maternal and paternal alleles conferred by allele-speciﬁc
epigenetic differences including DNA methylation or histone modiﬁca-
tions [17]. However, for a long time, themolecular marks of genomic im-
printing including differential methylation and monoallelic expression
could not be identiﬁed at chromosome 11q23 and chromosome band
11q13, where SDHD and SDHAF2 were located, respectively. The SDHD
gene shows bi-allelic expression in a number of non-paraganglionic
tissues [1]. The orthologous regions in mice containing the Sdhd and
Sdhaf2 genes on chromosome 9 show no evidence of imprinting [18],
even though many imprinted loci are conserved between mice and
human. In addition, paraganglioma tumors caused by germ line SDHD
mutations demonstrate somatic loss of heterozygosity (LOH) targeting
the unmutated maternal gene copy [19], suggesting that the maternal
allele is expressed in paraganglionic tissues at least at low levels. Finally,
as described below, paraganglioma development is recently suggested
after maternal transmission of SDHD mutations in two isolated cases.
These observations led to speculations that genomic imprinting might
not be the mechanism responsible for the parent of origin effects.
It has been proposed that a distinct maternally expressed imprinted
gene, presumably located within the imprinted gene clusters on the
short arm of chromosome 11, must be lost by somatic whole chromo-
some deletions before PGL tumor development [20]. According to this
model, when an SDHD mutation is inherited on the paternal allele,
loss of entire maternal chromosome 11 eliminates both the normal
non-imprinted maternal copy of SDHD and the putative maternally
expressed distant imprinted gene. In contrast,when the SDHDmutation
is inherited on the maternal allele, tumor development requires two
more somatic hits: one hit to remove the normal paternal copy of
SDHD and another hit to remove the maternal copy of the distant
imprinted gene. Because somatic removal of distinct chromosome 11
segments from both maternal and paternal chromosomes is probabilis-
tically unlikely, tumor development rarely occurs after the maternal
transmission of an SDHDmutation.
In summary, thismodel assumes that PGL tumordevelopment follows
an unusual three hit process whereby both alleles of SDHD and maternal
copy of a putative unlinked imprinted gene on chromosome 11 must be
lost before tumor development. Thismodel not only assumes a hypothet-
ical unlinked maternally imprinted gene essential for paraganglioma
tumor suppression, but also fails to explain why PGL tumors develop so
frequently after transmission of a single mutation in the SDHB or SDHC
genes, both located on chromosome 1. Because a requirement for the
third hit targeting the putative imprinted gene on chromosome11 should
also make mutations in SDHB or SDHC virtually non-penetrant. In con-
trast, abundant data show that penetrance of SDHB and SDHCmutations
are not low [2,21]. Therefore, the model incorporating somatic deletion
of a third unlinked imprinted locus appears inadequate to explain the
higher penetrance of SDH gene mutations in PGL.
Recently, paraganglioma development uponmaternal transmission of
SDHD mutations is observed in two cases from two families suggesting
violation of the parent of origin effect observed in hundreds of SDHD fam-
ilies. In the ﬁrst family, an 11 year old boy who inherited SDHD W42X
mutation from his mother developed jugulotympanic paraganglioma
[22]. The diagnosis of paraganglioma was suspected by angiography but
could not be conﬁrmed by histopathology. Remarkably, the tumor
regressed after embolization and no other tumor was seen in the follow
up exam performed 15 years later. In the second family, a histologically
conﬁrmed adrenal pheochromocytoma, the most common location for
sporadic pheochromocytomas, developed in a 26 year old woman who
inherited SDHD P81L mutation from her mother [23]. The tumor
showed somatic loss of heterozygosity involving the paternal SDHD
allele as well as maternal loss of markers at chromosome band
11p15. No other paraganglioma tumor was reported in the indexcase. It is notable that the expressivity of maternally transmitted
SDHD mutations in both cases appears rather weak compared to
that of the paternally-transmitted mutations in general. In the ﬁrst
index case, the jugulotympanic paraganglioma spontaneously regressed;
in the second index case, a single adrenal pheochromocytoma is detected.
In contrast, paternal transmission of SDHDmutations often causes highly
penetrant paragangliomas that continues to grow slowly and that com-
monly develop in multiple locations in head/neck or extra-adrenal loca-
tions. Thus, even if the maternal transmission of SDHD mutations rarely
causes PGL/PHEO, the resulting phenotype appears much milder com-
pared to the phenotype after paternal transmission. Thus, as far as the
penetrance and expressivity of the SDHDmutations is concerned, overall
genetic data strongly suggest that the maternal and paternal copies of
SDHD are functionally unequal, consistent with genomic imprinting.3. Molecular evidence of imprinting at the SDHD locus
The observations described above, including possible rare cases of
single tumor development aftermaternal transmission of riskmutations
and the loss of heterozygosity targeting the maternal allele in PGL1 tu-
mors, do not necessarily exclude a model based on quantitative tissue
speciﬁc imprinting to explain the strong parent-of origin effects ob-
served in the inheritance of SDHD and SDHAF2 mutations. It should be
noted that dosage of tumor suppressor genes strongly correlates with
their tumor suppressing capability. Classical tumor suppressor genes
often follow an autosomal dominant mode of transmission consistent
with haploinsufﬁciency which triggers abnormal cell divisions and
leads to tumor development following somatic loss of the normal un-
mutated allele. Accordingly, Pten-mediated tumor suppression appears
to be highly dosage-sensitive inmouse in that as little as a 20%difference
in gene expression may alter tumor suppressing capability of the Pten
gene [24]. Tissue speciﬁc imprinting is also common occurrence. A
recent analysis suggests that 28% of imprinted genes in mice may
be imprinted only in one speciﬁc tissue, most commonly in placenta
and brain [25]. Thus, a quantitative imprinting model with over-
expression of the SDHD paternal allele relative to the maternal allele in
paraganglionic tissues can explain the paternal transmission of tumor
risk and the advantage conferred by LOH involving the maternal allele
in the PGL1 tumors. Quantitative imprintingmodel has been also recent-
ly proposed byMuller [26] who argued that “reduced” expression of the
maternal SDHD allele relative to the paternal allele can explain the
imprinted tumor transmission because only a paternally transmitted
mutation could deplete the gene product enough to trigger the hypoxic
stimulation and tumor formation.
In support of the imprinting model, we recently identiﬁed a
tissue-speciﬁc differentially methylated CpG island (CGI) that serves
as an alternative promoter for a large intergenic non-coding RNA
(linc RNA), located 200 kb downstream (telomeric) of the SDHD gene
[27]. The linc RNA, which we referred as UPGL, marks a boundary be-
tween a gene-rich domain containing the SDHD gene and an approxi-
mately 800 kb long gene-desert. The methylation primarily occurred in
adrenal tissues and involved two successive HpaII restriction enzyme
sites. The UPGL alternative promoter has two CGIs, each measuring ap-
proximately 300 bps, separated by a truncated LINE repeat. CGI#1 con-
tains a strong CTCF/cohesin binding site. Whereas the more telomeric
CGI#2 contains two differentially methylated HpaII sites located 350 bp
from the CTCF/cohesion binding site. Using rare heterozygous fetal spec-
imens, we demonstrated unequal allelic methylation in fetal adrenal me-
dulla and brain. Maternal hypermehylation is established in one case
where maternal decidual tissue was available. Analysis of the alternative
promoter methylation in paraganglioma tumors showed that non-SDHD
tumors hadmoremethylation than SDHD tumors in these twoHpaII sites
suggesting that the maternal allelic loss that occurs in the SDHD tumors
eliminates the hypermethylated maternal allele. Finally, mono-allelic
expression of UPGL is demonstrated in adrenal gland and heart in one
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mic imprinting at a CpG island distant from the SDHD gene.
Molecular evidence of imprinting at a gene-desert boundary ﬂanking
the SDHD locus is not limited to differentialmethylation andmono-allelic
expression. We also noted remarkable genomic organizational similari-
ties between the well-studied IGF2-H19 imprinted genes and the
SDHD-UPGL genes. In both regions, the upstream genes, IGF2 and SDHD,
are protein-encoding, paternally expressed and located at a signiﬁcant
distance from the downstreamnon-coding RNA genesH19 andUPGL, re-
spectively. It is thought that imprinted co-regulation of IGF2 and H19
genes involves competition for a common enhancer located downstream
of both genes [28,29]. Enhancer competition is regulated by a chromatin
boundary formed by CTCF and cohesin proteins [30] that bind to
unmethylated maternal allele of a CpG island located upstream of the
H19 gene. This boundary prevents accessibility of the enhancer to IGF2
promoter and favors expression of H19 gene in the maternal allele.
Whereasmethylation of the CpG island in the paternal allele blocks bind-
ing of CTCF and cohesin and allows the enhancer-IGF2 promoter interac-
tion, favoring paternal IGF2 expression. Thus, a differentially-methylated
CpG island serves as an imprint control region in the IGF2/H19 locus by
differentially binding CTCF/Cohesin proteins.
Remarkably, we also identiﬁed a strong CTCF binding site within
the alternative promoter of the UPGL gene. However, in contrast to
the IGF2/H19 region the CTCF binding sitewithin the alternative promoter
was not methylated. The two differentially methylated HpaII sites are lo-
cated approximately 350 base pair telomeric to the core CTCF binding
site. As expected, we found strong CTCF binding in both the methylated
adrenal tissues and in unmethylated lung tissue. Surprisingly, strong
cohesin binding occurred in the methylated adrenal gland but not in
the unmethylated lung tissue. This ﬁnding suggests that cohesin engage-
ment to CTCFmay occur when the HpaII sites are methylated, possibly in
competition with a transcription factor binding to the HpaII sites. Occu-
pancy of unmethylated HpaII sites by transcription factors may competi-
tively block cohesin binding on the paternal allele. In contrast, blockage of
transcription factor binding to methylated HpaII sites (maternal allele)
may allow cohesin engagement to CTCF. It is conceivable that chromatin
architectural changes associatedwith allele-speciﬁc cohesin bindingmay
result in differential long-range accessibility of a downstreamenhancer to
the SDHD promoter (Fig. 1). Themodel predicts that when themethylat-
ed HpaII sites allows cohesin binding on the maternal allele, SDHD gene
expression is low as a consequence of blocked enhancer–promoter inter-
action. In contrast, unmethylated HpaII sites on the paternal allele blocks
cohesin binding which in turn allows enhancer–promoter interaction
resulting in increased SDHD gene expression.
It is notable that neitherUPGL nor its differentially-methylated alter-
native promoter could be identiﬁed in themouse orthologous region on
chromosome 9, suggesting that this imprinted locus was absent in the
common ancestor. Future work is needed to conﬁrm the molecular
marks of imprinting identiﬁed in this study and to test predictions of
the long-range imprinted regulation model including presence of a
SDHD enhancer downstream of UPGL. Whether the UPGL locus may
also be involved in long-range imprinting regulation of the SDHAF2
gene, which is located approximately 51 megabases upstream (centro-
meric) to SDHD on the long arm of chromosome 11 represents another
line of future experimental inquiry.
4. Other regulatory mechanisms involving SDH subunits
In addition to the imprinted regulation of SDHD and SDHAF2
genes, other SDH subunits may also be regulated by distinct genetic
and post-translational mechanisms.
5. SDHA
The SDHA gene appears distinct from SDHB, SDHC and SDHD in that
SDHA mutations have yet to be described in extended paragangliomafamilies. This ﬁnding suggests that penetrance of SDHA mutations may
be low. Tissue culture experiments show that downregulation of SDHB,
SDHC and SDHD, but not SDHA, by siRNA and drugs leads to increased
ROS levels and hypoxia-inducible factor alpha (HIF-alpha) stabilization
[31]. These ﬁndings suggest that SDHA might be expressed at much
higher levels than the other subunit genes and that heterozygous muta-
tions or downregulation by siRNA could not reduce protein levels enough
to trigger ROS formation. Thus differential gene expression might be one
mechanism of regulating SDH subunit activity.
A mouse knockout model of NAD(+)-dependent deacetylase,
SIRT3, shows that reversible deacetylation of the SdhA gene product
results in increased mitochondrial complex II activity [32]. When
NAD(+) levels are high, SIRT3 may increase complex II activity to in-
crease oxidative phosphorylation. SDHA protein product activity may
also be regulated by phosphorylation through the activity of Fgr tyro-
sine kinase [33]. Recently, it has been suggested that SDHA protein
product is also phosphorylated by c-Src protein kinase which may
regulate cell viability and ROS production [34]. Perhaps, an interplay
between phosphorylation and acetylation regulates complex II activ-
ity for cellular metabolic demands.
In addition to the post-translational regulation of SDHA protein
product, distinct SDHA alleles are maintained at high concentrations in
population. Sequence analysis of SDH structural subunits reveals an in-
creased rate of SDHA polymorphisms, including two commonmissense
variants Y629F and V657I, consistent with long-term balancing selec-
tion [35]. Balancing selection generally occurs when the heterozygote
individuals have a survival advantage compared to homozygous individ-
uals. Genetic signature of balancing selection in SDHA was present in
humans but not in chimpanzees, suggesting that the selection occurred
after the split of these species from their common ancestor. Selecting
agents and functional consequences of the variants maintained at high
frequencies are currently unclear.
6. SDHB
Analysis of SDHB transcripts derived from peripheral blood mono-
nuclear cells has uncovered a targeted C-to-U mutation converting an
arginine residue to a stop codon [36]. The mutation primarily occurs
in monocytes. This observation suggests that SDHB mRNA is targeted
by an unknown cytidine deaminase to decrease the gene dosage in cer-
tain blood cells. The biological signiﬁcance and the underlying mecha-
nism of this ﬁnding remain to be established.
7. Subunit composition change in lower organisms
While SDH is regulated by epigenetic mechanisms in human, changes
in subunit composition plays an important role in oxygen dependent
metabolism in lower organisms. Mitochondrial complex II has distinct
enzymatic characteristics in different stages of the parasite Ascaris Suum
(A. Suum). While larvae living in high oxygen concentrations use SDH,
adult parasite living in low oxygen concentrations of intestine uses fuma-
rate reductase (FRD) (reviewed in [37]). FRD uses fumarate as the ﬁnal
electron acceptor to produce succinate under anaerobic conditions. SDH
in larvae and FRD in adult A. Suum have different Sdha and Sdhd protein
products, whereas Sdhb protein product appears identical. Bacteria also
have distinct FRD and SDH enzymes employed depending on the avail-
ability of oxygen. Escherichia coli FRD and SDH enzymes share no com-
mon subunits. These observations suggest that hypoxic environments
are associated with a programmed switch in mitochondrial complex II
enzyme activity from SDH to FRD in certain organisms.
8. Conclusions
Epigenetic regulation of mitochondrial complex II involves diverse
mechanisms, including maternal imprinting of SDHD and SDHAF2
genes, RNA editing of SDHB gene and common polymorphisms of the
Cohesin
UPGLSDHD DMR Enhancer
Paternal allele 
Maternal allele 
=Transcription factor
=CpG methylation
=CpG island
=coding RNA
=non-coding RNA
X
CTCF
CTCF
=enhancer-binding protein
UPGLSDHD DMR Enhancer
Fig. 1. A model for long-range epigenetic regulation of SDHD by genomic imprinting. A cis-acting element such as an enhancer may gain access to the SDHD promoter on the pa-
ternal allele, because cohesin engagement to CTCF may be competitively inhibited by a transcription factor bound to unmethylated alternative UPGL promoter. This long-range in-
teraction may be blocked on the maternal allele where the alternative UPGL promoter is methylated, making the enhancer element instead available to the UPGL promoter.
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and regulatory subunit is required for the function of complex II, epige-
netic suppression of a single subunit is likely sufﬁcient to downregulate
the SDH enzymatic activity. Imprinted transmission pattern of SDHD and
SDHAF2mutations was the ﬁrst recognized evidence for epigenetic reg-
ulation of complex II. Studies in paraganglioma tumors demonstrate that
complete inactivation of complex II by individual subunit mutations ac-
tivates hypoxia inducible pathways. Thus, partial inactivation of complex
II by distinct epigenetic mechanisms may act in synergy with environ-
mental hypoxia to facilitate adaptation to low oxygen conditions.
Speciﬁcally, studies linking SDH regulation to hypoxia adaptation
include (a) dynamic regulation of complex II enzymatic activities
between FRD and SDH depending on oxygen availability in lower
organisms [37]; (b) recapitulation of a chronic hypoxic phenotype of
high altitudes (i.e., carotid body paragangliomas) by SDH mutations
[1]; and (c) constitutive upregulation of hypoxia-inducible pathways in
PGL tumors [38,39]. These ﬁndings collectively suggest that epigenetic
downregulation of mitochondrial complex II in human may provide an
advantage for early detection and/or adaptation to hypoxia in certain tis-
sues. The occurrence of tissue-speciﬁc imprinting of SDHD in paraganglia,
the most hypoxia sensitive tissue in the body, supports this conclusion.
Despite these observations, role of mitochondrial complex II in oxygen
sensing and signaling pathways remains poorly understood, although
both succinate [40] and ROS [31] were implicated as downstream mes-
sengers that activate hypoxia-inducible pathways. Future research on
epigenetic regulation of complex II subunits may help us better under-
stand how this central metabolic enzyme integrates oxygen availability
to diverse cellular processes.
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